Eribulin Mesylate Injection

Eribulin Mesylate Injection
Product Description

Generic Name: Eribulin Mesylate Injection
Indication: Metastatic breast cancer (CN, US, EU, Japan and other countries)
Liposarcoma (US, EU)
Soft tissue sarcoma (Japan and other countries)

Guidelines: 
 NCCN （2023V4）， CSCO （2023）， ESMO （2023）

Exclusivity: FDA PED 2027/07/08

Read more Show less

XILING LAB CO.,LTD

  • CN
  • 2017
    On CPHI since
  • 2
    Certificates
  • 50 - 99
    Employees
Company types
Generics/Biosimilars Manufacturer
Manufacturer/Innovator
Pharmaceutical company
Primary activities
Generic APIs producer
Pharmaceutical Company (generic finished products)
View company profile
Categories
more categories Show less
Specifications
  • Selling Points
    International Approvals/Standards; Quality Service
  • Supplied from
    China
More specifications Fewer specifications

XILING LAB CO.,LTD

  • CN
  • 2017
    On CPHI since
  • 2
    Certificates
  • 50 - 99
    Employees
Company types
Generics/Biosimilars Manufacturer
Manufacturer/Innovator
Pharmaceutical company
Primary activities
Generic APIs producer
Pharmaceutical Company (generic finished products)
View company profile

More Products from XILING LAB CO.,LTD (2)

  • Eribulin Mesylate (API)

    Product Eribulin Mesylate (API)

    Generic Name: Eribulin Mesylate Injection
    Indication: Metastatic breast cancer (CN, US, EU, Japan and other countries)
    Liposarcoma (US, EU)
    Soft tissue sarcoma (Japan and other countries)

    Guidelines: 
     NCCN （2023V4）， CSCO （2023）， ESMO （2023） ...
  • Lurbinectedin (API)

    Product Lurbinectedin (API)

    Generic Name: Lurbinectedin lyophilized powder
    Indication: Treatment of adult patients with metastatic small cell lung cancer (SCLC) with disease progression on or after platinum-based chemotherapy.

    Originator: Pharma Mar
    Approval: US: June. 2020        &nbs...

XILING LAB CO.,LTD resources (1)

  • Brochure-Xiling Lab's Product List

    Brochure Brochure-Xiling Lab's Product List

    Xiling Lab covers full chain of pharmaceutical industry with strong background and robust capabilities. We specialize in innovative XDC platform technology (especially linker-drug systems and conjugation technology) and highly complex generic products. I am writing to seek potential opportunity of becoming your supplier (both for development and commercial stage) of our excellent oncology APIs, including Lurbinectedin, Eribulin Mesylate and Trabectedin. Please kindly find our brochure for more information.